GEN Exclusives

More »

Best of the Web

More »
Jul 01, 2007 (Vol. 27, No. 13)

A-to-I RNA editing

URL:www.lehigh.edu/%7eswm3/A-to-IRNAeditingwebsite/index.html
  • Extensive reference collection, links
  • Database needed
Remember the “good old days” when the central dogma ruled and nucleic acids were largely looked at as giant unalterable cellular blueprints? The more we learn about DNA and RNA, the more this doctrine looks like a quaint convention of a simpler time. Indeed, molecular biology today recognizes not only that RNA information can flow to DNA (reverse transcription), and that eukaryotic genes are usually in pieces in the DNA and must be spliced to make mature (and useful) RNA, but also that RNA itself can be altered in several nonsplicing mechanisms collectively referred to as editing. RNA editing is a phenomenon whose occurrence is now recognized to take place in most eukaryotic organisms. It varies from insertion of bases at specific places in mRNAs (mostly in simple eukaryotes) to chemical modification of bases in most other eukaryotes. The latter process most commonly involves conversion of adenosine to inosine by action of adenosine deaminase. At the A-to-I RNA Editing website, you’ll find everything you need to know about this latter process and gain insights into its significance for the cells that perform it.
  • Key:
  • Strong Points
  • Weak Points
  • Ratings:
  • Excellent
  • Very Good
  • Good

*The opinions expressed are solely those of the author(s) and should not be construed as reflecting the viewpoints of the publisher, Genetic Engineering & Biotechnology News, Mary Ann Liebert, Inc., the publishing house, or employees and affiliates thereof.

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

New Drugs for Ebola

Do you think that biopharma companies should not have to go through the normal drug approval process in order to get potential life-saving therapies to Ebola patients more quickly?